California

The main California policy story over the last year is research infrastructure rather than adult-use reform. AB 1103 was chaptered on 10 Oct 2025 and moves the state closer to a “research-friendly but not access-creating” model by updating how the Research Advisory Panel handles Schedule I and II projects.###

A second important development is AB 2489, the proposed California Veterans’ Right to Try Act. As amended, the bill would allow the Research Advisory Panel to submit FDA investigational new drug applications for multisite veteran-focused clinical trials involving psilocybin, ibogaine or other Schedule I or II substances, but as of 29 Apr 2026 it was in Assembly Appropriations suspense and had not become law. Publication should therefore treat it as pending legislation only.###

Practical access remains constrained. Local resolutions in Oakland, San Francisco and Berkeley reduce local enforcement priority around certain entheogenic-plant conduct, but they do not override state or federal supply, manufacture, distribution or professional-practice laws. For researchers, that means California is still principally a trial-and-institution state rather than a regulated services state.###

California remains one of the deepest US research states. UCSF’s Translational Psychedelic Research Program says it studies psychedelic drugs as potentially transformative treatments and describes work spanning mood disorders, substance use disorders, movement disorders and chronic pain. UCSF’s public clinical-trials pages also show active psilocybin studies, including anorexia nervosa.###

UC Berkeley’s Center for the Science of Psychedelics is an interdisciplinary academic centre focused on psychedelic research and public education; Berkeley’s research pages say it was founded in Sep 2020 and is housed within the Helen Wills Neuroscience Institute.###

ClinicalTrials.gov search results also show California activity beyond a single campus. Relevant examples include a UCSF/Stanford-linked chronic low back pain study, a UC San Diego psilocybin-assisted therapy study for physician well-being, and California site activity in multicentre psilocybin programmes. California should therefore be characterised as a research-intensive jurisdiction even though it has no state-regulated non-FDA psychedelic services market.###

Implementation in California is mainly about research governance, not service-centre licensing. AB 1103 recast the Research Advisory Panel’s remit for California projects requiring administration of Schedule I or II controlled substances, created an expedited review process through 1 Jan 2028, and extended closed-session protections for confidential project review.###

That matters for sponsors and institutions because California has historically had an additional state review layer for certain controlled-substance research. AB 1103 makes that layer more operationally usable, but there is still no California analogue to Oregon or Colorado facilitator licensing, healing-centre licensing, or state-managed psilocybin product regulation.###

Operational uncertainty now sits mostly in pending legislation. If AB 2489 advances, California could become more distinctive in veteran-focused state-supported IND activity; if it stalls, the state remains a large research market without a dedicated state clinical-access scheme for classic psychedelics.###

California’s ecosystem is anchored by major academic institutions rather than state-regulated service operators. Verified in-state anchors include UCSF’s Translational Psychedelic Research Program, UC Berkeley’s Center for the Science of Psychedelics, and MAPS, whose website lists a San Jose mailing location.###

The municipal layer also matters. Oakland, San Francisco and Berkeley have all taken official deprioritisation steps, which makes California notable in local policy discourse even without statewide legal access. For conference, media and advocacy partners, that means California offers dense institutional and local-policy networks, but not a verified regulated psilocybin-care market.###

From a patient-access and investor perspective, California should therefore be framed as a research-and-policy ecosystem with conventional ketamine/esketamine care and robust academic visibility, not as a state with lawful retail or quasi-clinical access to psilocybin services.###

Over the next 12 to 24 months, California is more likely to keep progressing through research administration, university-led trials and veteran-focused legislative proposals than through a near-term statewide commercial psilocybin-services model. The key watchpoint is whether AB 2489 or successor legislation converts California’s research ambitions into a state-backed veteran trial infrastructure.###

For access and reimbursement, little suggests a near-term California-specific breakthrough beyond the existing ketamine/esketamine landscape and ordinary trial participation. Professional training may continue to expand informally and through academic education, but without state service licensing those developments should not be described as authorising clinical psychedelic practice.###